The read at a glance
Computed from the FY2026 annual filing. Full history and the components behind each score are in the app.
- Distress risk · Altman Z-Score 0.29 — distress zone — historically elevated failure riskWatch
- Earnings-manipulation signal · Beneish M -1.18 — flag raised, worth a closer lookWatch
- Earnings quality 78/100 — accruals in line with cashOK
Where the revenue comes from
Fiscal 2026, as INTEGRATED BIOPHARMA INC reports it. History and quarterly detail are in the app.
- Contract Manufacturing$42.4M
- Other Nutraceutical Business$1.5M
Latest filings
- 10-K · Annual report2026-09-25
- 8-K · Company announcement2026-09-25
- 8-K · Company announcement2026-08-20
- 8-K · Company announcement2026-07-02
- 8-K · Company announcement2026-05-08
In the full recordFree for 14 days
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about INTEGRATED BIOPHARMA INC, every answer cited to the official filings🔒
- The Intelligence Brief — added when INTEGRATED BIOPHARMA INC's brief passes our SEC-figure check🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.